Filter
1093
Filtered Results: 1093
Text search:
medicine
prices
Featured
Recommendations
89
New Publications
316
Language
Document type
No document type
565
Studies & Reports
294
Guidelines
93
Strategic & Response Plan
71
Manuals
32
Situation Updates
15
Fact sheets
11
Training Material
7
Resource Platforms
3
Infographics
2
Countries / Regions
Global
53
India
38
Kenya
34
Ukraine
28
Nepal
27
Syria
27
Uganda
24
Nigeria
20
Sierra Leone
19
Liberia
19
South Africa
19
Malawi
19
Zambia
18
Myanmar / Burma
18
Western and Central Europe
18
Africa
17
Latin America and the Carribbean
16
Ethiopia
14
Venezuela
14
Ghana
13
Bangladesh
13
Congo, Democratic Republic of
12
Tanzania
12
Mozambique
12
Zimbabwe
11
Cameroon
10
South Sudan
10
Rwanda
10
South–East Asia Region
10
Haiti
9
Philippines
9
Eastern Europe
9
Indonesia
8
Namibia
7
Moldova
7
Senegal
6
Pakistan
6
Yemen
6
West and Central Africa
6
Asia
6
Burkina Faso
5
Germany
5
Lebanon
5
Sudan
5
Central African Republic
5
Botswana
5
Middle East and North Africa
5
Guinea
4
Cambodia
4
Lesotho
4
East and Southern Africa
4
Jordan
3
Afghanistan
3
Benin
3
Eswatini/ Swaziland
3
Paraguay
3
Tajikistan
3
Somalia
2
Thailand
2
Brazil
2
North Macedonia
2
Colombia
2
Chile
2
Eastern Europe and Central Asia
2
Poland
2
Southern Africa
2
Russia
2
Romania
2
Kyrgyzstan
2
Georgia
2
Bosnia and Herzegovina
2
Mali
1
USA
1
Niger
1
Turkey
1
Egypt
1
Chad
1
China
1
Papua New Guinea
1
Argentina
1
Peru
1
Serbia
1
Ecuador
1
Bolivia
1
Libya
1
Guatemala
1
Madagascar
1
Sri Lanka
1
Palestine
1
Albania
1
Mongolia
1
Laos
1
Bulgaria
1
Estonia
1
Lithuania
1
Iran
1
Kazakhstan
1
Vietnam
1
Gabon
1
Turkmenistan
1
Japan
1
Mauritius
1
Authors & Publishers
Publication Years
Category
Countries
457
Clinical Guidelines
87
Public Health
63
Key Resources
32
Women & Child Health
25
Pharmacy & Technologies
17
Capacity Building
3
Toolboxes
HIV
105
COVID-19
102
Pharmacy
66
Mental Health
63
Conflict
54
AMR
49
TB
45
Planetary Health
39
Health Financing Toolbox
26
Global Health Education
24
Natural Hazards
23
NCDs
21
Ebola
16
Disability
14
Refugee
14
Rapid Response
11
Caregiver
11
NTDs
11
Cholera
2
Polio
1
Health Financing
1
Prices people pay for medicines.
2nd edition - Published in 2003, the first WHO/HAI medicine prices manual Medicine Prices – A ...
The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study
The Malawian government recently introduced cost-covering consultation fees for self-referral patients in tertiary public hospitals. Previously, patients received medicines free of charge in government-owned health facilities, but must pay elsewhere...
Including Therapeutic Food, Dietary Vitamin and Mineral Supplementation - 2nd edition
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...
WHO today published the new edition of its Model Lists of Essential Medicines and Essential Medicines for Children, which include new treatments for various cancers, insulin analogues and new oral <... for diabetes, new medicines to assist people who want to stop smoking, and new antimicrobials to treat serious bacterial and fungal infections.
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all. However, high prices for both new, patented medicines and older medicines, like insulin, continue to keep some essential medicines out of reach for many patients.
Background
Access to medicines is important for long‐term care of cardiovascular diseases and hypertension. This study provides a cross‐country assessment of availability, prices, and affordabi...
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...
Finding out where certain medicines are provided and comparing prices of those medicines is unnecessarily hard in Zimbabwe. Something has to be don...
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significa...
It is estimated that around 2 billion people worldwide do not have access to essential medicines. Access to medicines in the Eastern Mediterranean Region varies among countries, depending on their i...
Globally each year, millions of people suffer illness or lose their lives because the vaccines, medicines and diagnostic tests that they need are either unavailable or unaffordable – and this lack of access to ... is acute in low- and middle-in-
come countries (LMICs). While the COVID-19 pandemic laid this inequity bare, it also saw the pharmaceutical industry develop and bring new vaccines and treat- ments to market at unprecedented speed. As the world emerges from the worst
of this crisis, pharmaceutical companies are now at an important juncture, where lessons learned from the pandemic can prove pivotal in finding solutions to bridge long-standing gaps in access to medicine in LMICs.
The growing challenges for people in low and middle-income countries to access new medicines.
Analysis 58
PAHO Revolving Fund Vaccine Prices for 2023
The National pharmaceutical policy aligns itself to the Government vision for development of the health sector, as defined in Vision 2020, the Millennium Development Goals and the Economic Development for Poverty Reduction Strategy and the National Health Policy. The pharmacy policy addresses, among...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
The 6th edition of the essential medicine list has been developed based on the 5th edition list of essential medicines, the National Standard Treatment Guidelines and Protocols 2013, list of laborat...
